Gemphire Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, GEMP, Gemphire Therapeutics Inc, priceseries

Gemphire Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
7.69
Close
7.50
High
8.50
Low
7.25
Previous Close
0.30
Daily Price Gain
7.20
YTD High
21.59
YTD High Date
Aug 1, 2017
YTD Low
0.24
YTD Low Date
Dec 6, 2019
YTD Price Change
-1.70
YTD Gain
-18.48%
52 Week High
21.59
52 Week High Date
Aug 1, 2017
52 Week Low
0.24
52 Week Low Date
Dec 6, 2019
52 Week Price Change
-1.70
52 Week Gain
-18.48%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2017
8.34
Jan 24. 2017
10.07
12 Trading Days
20.80%
Link
LONG
Mar 20. 2017
10.12
Mar 29. 2017
10.66
7 Trading Days
5.27%
Link
LONG
Jun 28. 2017
12.27
Aug 2. 2017
19.13
24 Trading Days
55.89%
Link
LONG
Aug 28. 2017
8.59
Sep 12. 2017
9.19
10 Trading Days
7.03%
Link
LONG
Jan 18. 2018
7.92
Feb 2. 2018
9.63
11 Trading Days
21.54%
Link
LONG
Mar 1. 2018
7.00
Mar 13. 2018
7.51
8 Trading Days
7.23%
Link
LONG
May 31. 2018
6.20
Jun 11. 2018
6.75
7 Trading Days
8.83%
Link
LONG
Sep 5. 2018
1.57
Sep 25. 2018
2.04
14 Trading Days
29.89%
Link
LONG
Jan 11. 2019
0.89
Jan 29. 2019
1.03
11 Trading Days
15.44%
Link
LONG
Feb 22. 2019
1.18
Mar 8. 2019
1.32
10 Trading Days
11.71%
Link
LONG
Apr 1. 2019
1.19
Apr 12. 2019
1.25
9 Trading Days
5.68%
Link
Company Information
Stock Symbol
GEMP
Exchange
NasdaqGM
Company URL
http://www.gemphire.com
Company Phone
248-980-6538
CEO
Charles L. Bisgaier
Headquarters
Michigan
Business Address
17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA, MI 48152
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001638287
About

Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of dyslipidemia. Its product under the Gemcabene name is used an adjunctive therapy to reduce low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and triglycerides. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Northville, MI.

Description

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. Its product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. The company was founded in 2008 and is headquartered in Northville, Michigan.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading